Professional Seasonal Analysis for Trading

China SXT Pharmaceuticals, Inc. - Common Stock (SXTC)

Seasonality Analysis

Stocks 8 Years Analyzed

China SXT Pharmaceuticals, Inc. - Common Stock Annual Seasonality Statistics

131.61%
Avg Annual Return
31.0%
Avg Monthly Win Rate
4/12
Positive Months
8
Years Analyzed

China SXT Pharmaceuticals, Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -8.17%
50%
Weak
February 109.55%
25%
Weak
March -13.54%
13%
Very Weak
April -15.36%
13%
Very Weak
May BEST 109.76%
29%
Weak
June 8.18%
71%
Very Strong
July -17.42%
14%
Very Weak
August WORST -18.52%
14%
Very Weak
September -11.02%
43%
Weak
October -11.78%
14%
Very Weak
November -9.83%
43%
Weak
December 9.78%
43%
Weak

China SXT Pharmaceuticals, Inc. - Common Stock 2026 vs Historical Pattern

Current Position
0.18
Historical Avg Position
28.86
Deviation
-28.68
Performance
Significantly Below Average

China SXT Pharmaceuticals, Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for SXTC with overlay patterns, custom date ranges, and more.

Create Free Account

China SXT Pharmaceuticals, Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

China SXT Pharmaceuticals, Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for SXTC across multiple timeframes.

Create Free Account

About China SXT Pharmaceuticals, Inc. - Common Stock (SXTC) Seasonality

China SXT Pharmaceuticals, Inc. - Common Stock (SXTC) has been analyzed using 8 years of historical data to identify seasonal patterns. Classified under Stocks, China SXT Pharmaceuticals, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for China SXT Pharmaceuticals, Inc. - Common Stock is historically May, with an average return of 109.76% and a win rate of 29%. Conversely, August tends to be the weakest month, averaging -18.52% return.

Looking at the full calendar year, China SXT Pharmaceuticals, Inc. - Common Stock has an average annual return of 131.61% with an overall monthly win rate of 31.0%. Out of 12 months, 4 typically show positive average returns.

The seasonal pattern for China SXT Pharmaceuticals, Inc. - Common Stock has a consistency score of 62.7 (Good), based on 8 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

China SXT Pharmaceuticals, Inc. - Common Stock Seasonality FAQ

What is the best month to buy China SXT Pharmaceuticals, Inc. - Common Stock (SXTC)?

Historically, May has been the best month for China SXT Pharmaceuticals, Inc. - Common Stock, with an average return of 109.76% and a win rate of 29%. However, past performance does not guarantee future results.

What is the worst month for China SXT Pharmaceuticals, Inc. - Common Stock (SXTC)?

Based on historical data, August has been the weakest month for China SXT Pharmaceuticals, Inc. - Common Stock, with an average return of -18.52%. This is a historical observation and does not guarantee future results.

How reliable is SXTC seasonality data?

The seasonality analysis for China SXT Pharmaceuticals, Inc. - Common Stock is based on 8 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use China SXT Pharmaceuticals, Inc. - Common Stock seasonality in my trading?

Use China SXT Pharmaceuticals, Inc. - Common Stock (SXTC) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.